Further evaluation of the CKD cohort separated into Stage 3a, 3b, 4, or 5 CKD, or comparing those on diuretics vs. not, and on sodium-glucose co-transporter 2-inhibitors (SGLT2-i) vs. not, showed no difference in kidney disease specific component scores but numbers were small in each group. Here, SLC5A2 is linked to kidney disorder.